These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 7190083)

  • 1. Cyclophosphamide and cis-dichlorodiammine platinum (11). Nonempiric scheduling to spare dose-limiting tissues in the rat.
    Tew KD; Taylor DM
    Cancer Chemother Pharmacol; 1980; 4(2):103-9. PubMed ID: 7190083
    [No Abstract]   [Full Text] [Related]  

  • 2. High-dose methotrexate with cyclophosphamide and cis-platinum in treatment of advanced ovarian carcinoma.
    Lele SB; Piver MS; Barlow JJ
    Gynecol Oncol; 1979 Aug; 8(1):74-7. PubMed ID: 313358
    [No Abstract]   [Full Text] [Related]  

  • 3. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.
    Ehrlich CE; Einhorn L; Williams SD; Morgan J
    Cancer Treat Rep; 1979 Feb; 63(2):281-8. PubMed ID: 376134
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative cytotoxic properties of ifosfamide and cyclophosphamide in rat solid tumor and normal tissues.
    Tew KD
    Semin Oncol; 1982 Dec; 9(4 Suppl 1):24-7. PubMed ID: 7163812
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of cis-dichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumour-bearing rats.
    Taylor DM; Tew KD; Jones JD
    Eur J Cancer (1965); 1976 Apr; 12(4):249-54. PubMed ID: 954790
    [No Abstract]   [Full Text] [Related]  

  • 6. Studies with cyclophosphamide labeled with phosphorus-32: nucleic acid alkylation and its effect on DNA synthesis in rat tumor and normal tissues.
    Tew KD; Taylor DM
    J Natl Cancer Inst; 1977 May; 58(5):1413-9. PubMed ID: 857031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
    Myers CE; Young RC; Chabner BA
    Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic aids to proper chemotherapeutic scheduling: labeled nucleoside incorporation studies in vivo.
    Young RC
    Cancer Treat Rep; 1976 Dec; 60(12):1947-58. PubMed ID: 1026349
    [No Abstract]   [Full Text] [Related]  

  • 9. Adriamycin/cis-platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland.
    Alberts DS; Manning MR; Coulthard SW; Koopmann CF; Herman TS
    Cancer; 1981 Feb; 47(4):645-8. PubMed ID: 7194729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
    Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Dichlorodiammineplatinum(II) in non-small cell carcinoma of the lung.
    Gralla RJ; Cvitkovic E; Golbey RB
    Cancer Treat Rep; 1979; 63(9-10):1585-8. PubMed ID: 498158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of methotrexate on the uptake of de novo and salvage precursors into the DNA of rat tumours and normal tissues.
    Tew KD; Taylor DM
    Eur J Cancer (1965); 1977 Mar; 13(3):279-89. PubMed ID: 862645
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of advanced ovarian cancer with cis-dichlorodiammine platinum in combination with cyclophosphamide. An E.C.O.G. pilot study.
    Israel L; Aguilera J; Breau JL
    Am J Clin Oncol; 1983 Feb; 6(1):85-9. PubMed ID: 6682285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer.
    Kelsen D; Gralla R; Stoopler M; Casper E; Cheng E; Kosloff C; Golbey R
    Cancer Treat Rep; 1982 Feb; 66(2):247-51. PubMed ID: 7034932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid tumor models for the assessment of different treatment modalities: VIII. The scheduling of treatment for a chemotherapeutically resistant experimental solid tumor.
    Looney WB; Hopkins HA; MacLeod MS
    Cancer; 1979 Apr; 43(4):1201-10. PubMed ID: 445323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferative defects in renal and intestinal epithelium after cis-dichlorodiammine platinum (II).
    Kovacs CJ; Braunschweiger PG; Schenken LL; Burholt DR
    Br J Cancer; 1982 Feb; 45(2):286-94. PubMed ID: 7199350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of schedule in adriamycin/cyclophosphamide combination chemotherapy.
    Yesair DW; McNitt S; Tobias J; Wodinsky I
    Eur J Cancer (1965); 1978 Feb; 14(2):141-6. PubMed ID: 624311
    [No Abstract]   [Full Text] [Related]  

  • 18. The effectiveness of cis-platinum, cyclophosphamide and melphalan in treating disseminated tumor cells in mice.
    Kanclerz A; Chapman JD
    Clin Exp Metastasis; 1987 Sep; 5(3):199-211. PubMed ID: 3652551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum (II) by infusion in patients with adenocarcinoma and large cell carcinoma of the lung.
    Eagan RT; Frytak S; Creagan ET; Ingle JN; Kvols LK; Coles DT
    Cancer Treat Rep; 1979; 63(9-10):1589-91. PubMed ID: 227597
    [No Abstract]   [Full Text] [Related]  

  • 20. [Nephrotoxicity and myelotoxicity of antineoplastic Pt(II) and Pt(IV) coordination compounds in rats].
    Horn U; Härtl A; Neuhaus G; Stöckel U; Schröer HP; Hoffmann H
    Arch Geschwulstforsch; 1989; 59(4):245-50. PubMed ID: 2802932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.